nanolipolee-007

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namenanolipolee-007
Drug Alias Nameleelamine hydrochlorideleelamine
ClassificationNatural product/ExtractSmall molecules
Mechanisms of ActionMitogen-activated protein kinase inhibitorsSerine/threonine-protein kinase B-raf inhibitorsPI3-kinase class I inhibitors +[5] 
TargetsSerine/threonine-protein kinase AKT3Signal transducer and activator of transcription 3Serine/threonine-protein kinase B-raf +[5] 
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPennsylvania State University
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMelanovus Oncology IncPennsylvania State UniversityCipher Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsMelanoma

Other Information

ATC CodeN/A
Related LinksN/A